Your browser doesn't support javascript.
loading
The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.
Rosenbohm, Angela; Hirsch, Susanne; Volk, Alexander E; Grehl, Torsten; Grosskreutz, Julian; Hanisch, Frank; Herrmann, Andreas; Kollewe, Katja; Kress, Wolfram; Meyer, Thomas; Petri, Susanne; Prudlo, Johannes; Wessig, Carsten; Müller, Hans-Peter; Dreyhaupt, Jens; Weishaupt, Jochen; Kubisch, Christian; Kassubek, Jan; Weydt, Patrick; Ludolph, Albert C.
Afiliación
  • Rosenbohm A; Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
  • Hirsch S; Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
  • Volk AE; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
  • Grehl T; Institute of Human Genetics, University of Ulm, Ulm, Germany.
  • Grosskreutz J; Department of Neurology, Alfried Krupp Krankenhaus Rüttenscheid, Essen, Germany.
  • Hanisch F; Department of Neurology, University of Jena, Jena, Germany.
  • Herrmann A; Department of Neurology, University of Halle, Halle, Germany.
  • Kollewe K; Department of Neurology and German Center for Neurodegenerative Diseases (DZNE), Research Site Dresden, Technische Universität Dresden, Dresden, Germany.
  • Kress W; Department of Neurology, Medical School Hannover, Hannover, Germany.
  • Meyer T; Institute of Human Genetics, University of Würzburg, Würzburg, Germany.
  • Petri S; Department of Neurology, Outpatient Clinic for ALS and Other Motor Neuron Disorders, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Prudlo J; Department of Neurology, Medical School Hannover, Hannover, Germany.
  • Wessig C; Department of Neurology and German Center for Neurodegenerative Diseases (DZNE), Rostock University Medical Center, Rostock, Germany.
  • Müller HP; Department of Neurology, Bavaria Clinic, Bad Kissingen, Germany.
  • Dreyhaupt J; Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
  • Weishaupt J; Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
  • Kubisch C; Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
  • Kassubek J; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
  • Weydt P; Institute of Human Genetics, University of Ulm, Ulm, Germany.
  • Ludolph AC; Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
J Neurol ; 265(5): 1026-1036, 2018 May.
Article en En | MEDLINE | ID: mdl-29464380
ABSTRACT

OBJECTIVE:

Spinal and bulbar muscular atrophy (SBMA) is caused by an abnormal expansion of the CAG repeat in the androgen receptor gene. This study aimed to systematically phenotype a German SBMA cohort (n = 80) based on laboratory markers for neuromuscular, metabolic, and endocrine status, and thus provide a basis for the selection of biomarkers for future therapeutic trials.

METHODS:

We assessed a panel of 28 laboratory parameters. The clinical course and blood biomarkers were correlated with disease duration and CAG repeat length. A subset of 11 patients was evaluated with body fat MRI.

RESULTS:

Almost all patients reported muscle weakness (99%), followed by dysphagia (77%), tremor (76%), and gynecomastia (75%) as major complaints. Creatine kinase was the most consistently elevated (94%) serum marker, which, however, did not relate with either the disease duration or the CAG repeat length. Paresis duration and CAG repeat length correlated with dehydroepiandrosterone sulfate after correction for body mass index and age. The androgen insensitivity index was elevated in nearly half of the participants (48%).

CONCLUSIONS:

Metabolic alterations in glucose homeostasis (diabetes) and fat metabolism (combined hyperlipidemia), and sex hormone abnormalities (androgen insensitivity) could be observed among SBMA patients without association with the neuromuscular phenotype. Dehydroepiandrosterone sulfate was the only biomarker that correlated strongly with both weakness duration and the CAG repeat length after adjusting for age and BMI, indicating its potential as a biomarker for both disease severity and duration and, therefore, its possible use as a reliable outcome measure in future therapeutic studies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atrofia Muscular Espinal Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: J Neurol Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atrofia Muscular Espinal Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: J Neurol Año: 2018 Tipo del documento: Article País de afiliación: Alemania
...